阿立哌唑与喹硫平治疗精神分裂症的疗效和安全性  

Efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia

作　　者：王占敏[1] 宓为峰[2] 王晓志[2] 卢天兰[2] 付艺[2] 王雪芹[2] 郝晓楠[2] 李玲芝[2] 张鸿燕[2] 

机构地区：[1]河北省荣军医院精神科,河北保定071000 [2]北京大学第六医院卫生部精神卫生学重点实验室,北京100191

出　　处：《中国临床药理学杂志》2012年第12期941-943,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：目的评价阿立哌唑与喹硫平治疗精神分裂症的疗效及安全性。方法169例符合DSM-Ⅳ(第4版)精神分裂症患者,阿立哌唑组79例,剂量10～30mg·d-1;喹硫平组90例,剂量400～750 mg·d-1,疗程均8周。治疗前,治疗第4,8周用阳性和阴性症状量表(PANSS)评价主要疗效。用实验室检查、生命体征、心电图等评价安全性。结果 2组治疗4,8周PANSS总分均较治疗前有显著下降(P均<0.01),治疗8周末,PANSS总分减分差值及疗效2组间差异无统计学意义。2组药物不良反应发生率分别为25.3%(20/79)和17.7%(16/90)。阿立哌唑组对心率的影响较喹硫平组小;阿立哌唑组甘油三酯水平和心电图QRS间期较治疗前变化明显(P<0.05)。喹硫平组心率、体重、体重指数、血红蛋白、总胆固醇和低密度脂蛋白较治疗前变化明显(P<0.01)。结论阿立哌唑与喹硫平对精神分裂症疗效相当,两者所致不良反应发生率相近。Objective To investigate the clinical efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia. Methods A randomized, controlled clinical trial was designed. One hundred and sixty -nine patients with schizophrenia were randomized into aripiprazole group （n =79, 8 weeks,10-30 mg. d-1） and quetiapine group （n = 90, 8 weeks, 400 -750 mg . d-1 ）. The positive and negative syndrome scale （PANSS） and response rate were mainly used to evaluate efficacy. The safety was assessed by using the laboratory examination, vital signs and electrocardiogram （ECG） at the baseline, week 4, 8. Results Compared with the baseline, total scores of PANSS in both groups de- creased significantly at week 4 and week 8 （P 〈 0.01 ）. At week 8 of treatment the mean reduction scores of PANSS and the clinical response rates were approximate, there were no significant differences between both groups. The incidence of adverse drug reactions related to the drugs 25.3% （20/79） in aripiprazole and 17.7% （16/90）in quetiapine treat- ment was approximate in both groups, with lower liability for heart rate in aripiprazole than in quetiapine treatment. The tfiglyceride（TG） and QRS interval in aripiprazole group showed more significant differences at week 8 than the baseline （P 〈 0.05）. But the heart rate, body mass, body mass index （ BMI）, hemoglobin （ HGB ）, total cholesterol （ TC ） and low density lipoprotein （LDL） in quetiapine group different significantly when compared with those at baseline （ P 〈 0. 01 ）. Conclusion Aripi- prazole and quetiapine both have good efficacy in the treatment ofschizophrenia. They have similar incidence of adverse drug reaction related to the drugs.

关 键 词：阿立哌唑 喹硫平 精神分裂症 疗效 安全性 

分 类 号：R971.4[医药卫生—药品] R949[医药卫生—药学]